The Utility Of Minimal Residual Disease (MRD) Assessment At First Relapse: Results From The BSBMT/Ukmf Myeloma X (Intensive) Trial

被引：1
|
作者：
Ashcroft, John
de Tute, Ruth M.
Cairns, David A.
Fletcher, Marie
Owen, Roger G.
Rawstron, Andy
O'Connor, Sheila J. M.
Williams, Cathy D.
Snowden, John A.
Cavenagh, J. D.
Parrish, Christopher
Morris, Treen
Brown, Julia M. B.
Cook, Gordon
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.3378.3378
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3378
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Minimal residual disease (MRD) assessment after allogeneic BMT for childhood acute lymphoblastic leukaemia (ALL) allows early prediction of relapse.
    Knechtli, C
    Goulden, N
    Harris, E
    Hancock, J
    Jones, C
    Grandage, V
    Garland, R
    Potter, M
    Cornish, J
    Pamphilon, D
    Steward, C
    Oakhill, A
    BLOOD, 1997, 90 (10) : 2431 - 2431
  • [32] MINIMAL RESIDUAL DISEASE (MRD) BY MULTIPARAMETER FLOW CYTOMETRY (MFC) AND NEXT-GENERATION SEQUENCING (NGS) IN NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (NDMM): RESULTS FROM THE FORTE TRIAL
    Oliva, S.
    Genuardi, E.
    Rota-Scalabrini, D.
    Zamagni, E.
    Auclair, D.
    Jacob, A. P.
    Zambello, R.
    Spadano, A.
    Giuliani, N.
    Cuoghi, A.
    De Rosa, L.
    Visca, L.
    Gozzetti, A.
    Pietrantuono, G.
    Patriarca, F.
    de Fabritiis, P.
    Aquino, S.
    Kirsch, I. R.
    Offidani, M.
    Belotti, A.
    Musto, P.
    Boccadoro, M.
    Gay, F.
    HAEMATOLOGICA, 2021, 106 (10) : 74 - 74
  • [33] The utility of non-invasive liquid biopsy for mutational analysis and minimal residual disease assessment in extramedullary multiple myeloma
    Long, Xiaolu
    Xu, Qian
    Lou, Yaoyao
    Li, Chunrui
    Gu, Jia
    Cai, Haodong
    Wang, Di
    Xu, Jinhuan
    Li, Tongjuan
    Zhou, Xiaoxi
    Xiao, Min
    Wang, Ying
    Mao, Xia
    Zhou, Jianfeng
    Chen, Liting
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (02) : E45 - E48
  • [34] Clinical Utility of Next-Generation Flow-Based Minimal Residual Disease Assessment in Patients with Multiple Myeloma
    Kim, Hyun-Young
    Yoo, In Young
    Lim, Dae Jin
    Kim, Hee-Jin
    Kim, Sun-Hee
    Yoon, Sang Eun
    Kim, Seok Jin
    Cho, Duck
    Kim, Kihyun
    ANNALS OF LABORATORY MEDICINE, 2022, 42 (05) : 558 - +
  • [35] Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
    Medina, Alejandro
    Puig, Noemi
    Flores-Montero, Juan
    Jimenez, Cristina
    Sarasquete, M. -Eugenia
    Garcia-Alvarez, Maria
    Prieto-Conde, Isabel
    Chillon, Carmen
    Alcoceba, Miguel
    Gutierrez, Norma C.
    Oriol, Albert
    Rosinol, Laura
    Blade, Joan
    Gironella, Mercedes
    Hernandez, Miguel T.
    Gonzalez-Calle, Veronica
    Cedena, Maria-Teresa
    Paiva, Bruno
    San-Miguel, Jesus F.
    Lahuerta, Juan-Jose
    Mateos, Maria-Victoria
    Martinez-Lopez, Joaquin
    Orfao, Alberto
    Gonzalez, Marcos
    Garcia-Sanz, Ramon
    BLOOD CANCER JOURNAL, 2020, 10 (10)
  • [36] Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
    Alejandro Medina
    Noemi Puig
    Juan Flores-Montero
    Cristina Jimenez
    M.-Eugenia Sarasquete
    María Garcia-Alvarez
    Isabel Prieto-Conde
    Carmen Chillon
    Miguel Alcoceba
    Norma C. Gutierrez
    Albert Oriol
    Laura Rosinol
    Joan Bladè
    Mercedes Gironella
    Miguel T. Hernandez
    Veronica Gonzalez-Calle
    Maria-Teresa Cedena
    Bruno Paiva
    Jesus F. San-Miguel
    Juan-Jose Lahuerta
    Maria-Victoria Mateos
    Joaquin Martinez-Lopez
    Alberto Orfao
    Marcos Gonzalez
    Ramon Garcia-Sanz
    Blood Cancer Journal, 10
  • [37] Evaluation of hemodilution influence on bone marrow minimal residual disease (MRD) assessment in multiple myeloma patients via assessing mast cell abundance
    Wangemann, J.
    Stuebig, T.
    Sanoja-Flores, L.
    Boettcher, S.
    Chitadze, G.
    Novakova, M.
    Szczepanowski, M.
    Einsele, H.
    Kneba, M.
    Flores-Montero, J.
    Brueggemann, M.
    Ritgen, M.
    Orfao, A.
    Knop, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 104 - 104
  • [38] ASSESSMENT OF MINIMAL RESIDUAL DISEASE (MRD) IN AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELL (PBSC) TRANSPLANTATION FOR MULTIPLE-MYELOMA (MM)
    JUREMA, M
    HUNGER, S
    NEGRIN, R
    CLEARY, M
    BLOOD, 1993, 82 (10) : A431 - A431
  • [39] Minimal residual disease (MRD) in patients with resected stage I NSCLC: Results of the prospective adjuvant IFCT-0703 trial.
    Vasseur, Damien
    Jovelet, Cecile
    Cozic, Nathalie
    Mazieres, Julien
    Barlesi, Fabrice
    Bennouna, Jaafar
    Gervais, Radj
    Moreau, Lionel
    Berard, Henri
    Molinier, Olivier
    Moro-Sibilot, Denis
    Souquet, Pierre Jean
    Amour, Elodie
    Morin, Franck
    Zalcman, Gerard
    Soria, Jean-Charles
    Westeel, Virginie
    Lacroix, Ludovic
    Besse, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach
    Guolo, Fabio
    Minetto, Paola
    Clavio, Marino
    Miglino, Maurizio
    Colombo, Nicoletta
    Cagnetta, Antonia
    Cea, Michele
    Marcolin, Riccardo
    Todiere, Andrea
    Ballerini, Filippo
    Gobbi, Marco
    Lemoli, Roberto Massimo
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (06) : E223 - E225
12345